

AWARD NUMBER: CDMRPL-16-0-DM160475

TITLE: Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry

PRINCIPAL INVESTIGATOR: Jeffrey Livezey, LTC, MC, USA

CONTRACTING ORGANIZATION: Uniformed Services University, Bethesda, MD

REPORT DATE: June 2021

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MMM-YYYY) June 2021		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 22MAY2020 – 21MAY2021	
4. TITLE AND SUBTITLE Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry				5a. CONTRACT NUMBER CDMRPL-16-0-DM160475	
				5b. GRANT NUMBER DM160475	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) LTC Jeffrey Livezey E-Mail: Jeffrey.r.livezey.mil@mail.mil				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Uniformed Services University Clinical Research Unit, BLDG 53, Dept of Medicine Bethesda, MD 20814				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command (USAMRDC) Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) USAMRDC	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study. The protocol has been approved by the USUHS IRB and the business contract is currently being reviewed.					
15. SUBJECT TERMS mefloquine, PTSD, pharmacogenomics, drug adverse events					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

1. INTRODUCTION.....	4
2. KEYWORDS	4
3. ACCOMPLISHMENTS.....	4
What were the major goals of the project? (Goals to be accomplished and status.)	4
What was accomplished under these goals? (Detailed progress and results.)	4
What opportunities for training and professional development has the project provided?.....	5
How were the results disseminated to communities of interest?	5
Plans for the next reporting period to accomplish the goals	5
4. IMPACT.....	5
What was the impact on the development of the principal discipline(s) of the project?	5
What was the impact on other disciplines?.....	5
What was the impact on technology transfer?	5
What was the impact on society beyond science and technology?.....	5
5. CHANGES/PROBLEMS	5
Changes in approach and reasons for change	5
Actual or anticipated problems or delays and actions or plans to resolve them	5
Changes that had a significant impact on expenditures	5
Significant changes in use or care of human subjects.....	5
Significant changes in use or care of vertebrate animals	6
Significant changes in use of biohazards and/or select agents.....	6
6. PRODUCTS	6
Website(s) or other Internet site(s)	6
Technologies or techniques	6
Inventions, patent applications, and/or licenses.....	6
Other Products	6
7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS	7
What individuals have worked on the project?.....	7
Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?	7
What other organizations were involved as partners?	7
8. SPECIAL REPORTING REQUIREMENTS.....	7
9. APPENDICES.....	7

1. INTRODUCTION

The purpose of this study is to investigate possible pharmacogenomic risk factors for mefloquine neurotoxicity and potentially find markers that may differentiate between mefloquine toxicity and PTSD. This study is a pilot study powered to find large, clinically significant differences in genetic variants along with exploratory objectives aimed at looking for trends in symptom complexes, environmental interactions with various genetic markers and differences between mefloquine toxicity and PTSD. The subject population includes anyone with a mefloquine exposure history or diagnosis of PTSD without mefloquine exposure. The study is a cross-sectional case-control study of three groups (1) exposure to mefloquine and had, or continue to have, neuropsychiatric symptoms after exposure (100 subjects), 2) exposure to mefloquine and had no neuropsychiatric symptoms (100 subjects) or 3) had no mefloquine exposure and have a diagnosis of PTSD (50 subject). Subjects will be consented and screened at the Uniformed Services University (USU) Clinical Trials Unit. Once enrolled, subjects will provide a pertinent medical history and if available, have medical records reviewed. They will also complete various validated neuropsychiatric assessments, which are components of the validated NIH Toolbox. Subjects will then have blood drawn for the pharmacogenomic testing, which will be stored in a freezer in BLDG 53 and then be batch analyzed by the TAGC genomic testing laboratory at USU targeting genetic variants of the following genes identified in the medical literature: Alpha-one acid glycoprotein, MDR1, MTHFR, Pyk2, 5HT2a, ADA, A2A, CYP3A4.

2. KEYWORDS

Mefloquine, drug toxicity, pharmacogenomics, neurotoxicity, clinical pharmacology

3. ACCOMPLISHMENTS

What were the major goals of the project? (Goals to be accomplished and status.)

Specific Aim 1: Determine if there is a single or pattern of genomic risk factors for patients who develop mefloquine neuropsychiatric toxicity

Specific Aim 2: Determine if there is a pharmacogenetic risk factor for developing chronic (>6 months) mefloquine neurotoxicity

Specific Aim 3: Determine if there is a relationship between mefloquine toxicity and development of post-traumatic stress disorder (PTSD) with an emphasis on pharmacogenomic risk factors

Specific Aim 4: Determine if there is a way to distinguish between subjects with chronic mefloquine neurotoxicity and subjects with PTSD

Major Task 1: Prepare Research Case Control Protocol (months 1-8) – 100% complete

Major Task 2: Coordinate Study Staff for Study (month 7) – 100% complete

Major Task 3: Clinical Study (months 8-30) – 15% complete

Major Task 4: Genotyping of various genes (months 6-32) – 0% complete

Major Task 5: Data Analysis (months 32-36) – 0% complete

What was accomplished under these goals? (Detailed progress and results.)

All research at USU which is not related to COVID-19 was put on hold for **most of this reporting period**. There was minimal progress made on the study. Enrollment resumed at the end of May 2020. We have been able to enroll 3 subjects since re-opening the study. To date, 36 subjects have been enrolled, goal 250 subjects. Due to his retirement, Col Oliver was replaced as PI with LTC Livezey.

What opportunities for training and professional development has the project provided?

Nothing to report

How were the results disseminated to communities of interest?

Nothing to report

Plans for the next reporting period to accomplish the goals

Continue to expand recruitment efforts within and outside of the USUHS/WRNMMC area.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

Nothing to report

What was the impact on other disciplines?

Nothing to report

What was the impact on technology transfer?

Nothing to report

What was the impact on society beyond science and technology?

Nothing to report

5. CHANGES/PROBLEMS

Changes in approach and reasons for change

Nothing to report

Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to report now that we are allowed to resume study activities

Changes that had a significant impact on expenditures

Nothing to report

Significant changes in use or care of human subjects

TOTAL PROTOCOL(S): 1
IRB Protocol Number: MED-83-9137 (MED-93-9137)
HRPO Protocol Number: Exempt
Protocol PI: Thomas Oliver
Protocol Site: USU

Protocol Title: Evaluation of Multiple Potential Pharmacogenomic Risk Factors for Chronic Mefloquine Neurotoxicity through the Establishment of a Drug Safety Registry

Target approved for clinical significance: 250 subjects

IRB INITIAL APPROVAL DATE: 01/11/2019

HRPO INITIAL APPROVAL DATE: 04/14/2017 (HRPO determined exempt from review b/c research is at DOD lab)

CONTINUING REVIEWS APPROVAL DATES:

- 19 Jan 2021 (exp. 1 Feb 2022)

AMENDMENTS:

- Replacing COL(ret) Oliver with LTC Livezey as PI (ref. 934250)
- Adding Roshila Mohamed as CRC and modifying recruitment flyer (ref. 934542)

ENROLLMENT STATUS:

Number of subjects recruited/original planned target: 166/no recruitment limit

Number of subjects screened/original planned target: 156/no screening limit

Number of patients enrolled/original planned target: 36/250

Number of patients completed/original planned target: 36/250

ADVERSE EVENTS OR UNANTICIPATED PROBLEMS:

- none

Significant changes in use or care of vertebrate animals

No animal use research is involved.

Significant changes in use of biohazards and/or select agents

No biohazard or select agent research is involved.

6. PRODUCTS

Journal publications

Nothing to Report

Books or other non-periodical, one-time publications

Nothing to Report

Other publications, conference papers, and presentations

Nothing to Report

Website(s) or other Internet site(s)

Nothing to Report

Technologies or techniques

Nothing to Report

Inventions, patent applications, and/or licenses

Nothing to Report

Other Products

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

<i>Name:</i>	COL Thomas Oliver
<i>Project Role:</i>	PI
<i>Researcher Identifier:</i>	
<i>Nearest person month worked:</i>	2.5
<i>Contribution to Project:</i>	Coordination with protocol amendment modification and submission process. Assisted with neurobehavioral assessment process
<i>Name:</i>	AI/PI
<i>Project Role:</i>	
<i>Researcher Identifier:</i>	
<i>Nearest person month worked:</i>	2.5
<i>Contribution to Project:</i>	Coordination with protocol amendment modification and submission process. Assisted with neurobehavioral assessment process.
<i>Name:</i>	Dutchabong Shaw, RN, BSN, MA, CCRP
<i>Project Role:</i>	Research Coordinator
<i>Researcher Identifier:</i>	
<i>Nearest person month worked:</i>	4.0
<i>Contribution to Project:</i>	Coordinated neurobehavioral assessment process.
<i>Name:</i>	Joshua Gray, PhD
<i>Project Role:</i>	Clinical Psychologist
<i>Researcher Identifier:</i>	
<i>Nearest person month worked:</i>	1.0
<i>Contribution to Project:</i>	Reviewed and modified the neurobehavioral test battery.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to Report

What other organizations were involved as partners?

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

QUAD CHART

Convert this report to a PDF file and append updated quarterly Quad Chart in PDF as an appendix.

9. APPENDICES

Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.